Literature DB >> 21903077

Nitration of tyrosine 10 critically enhances amyloid β aggregation and plaque formation.

Markus P Kummer1, Michael Hermes, Andrea Delekarte, Thea Hammerschmidt, Sathish Kumar, Dick Terwel, Jochen Walter, Hans-Christian Pape, Simone König, Sigrun Roeber, Frank Jessen, Thomas Klockgether, Martin Korte, Michael T Heneka.   

Abstract

Part of the inflammatory response in Alzheimer's disease (AD) is the upregulation of the inducible nitric oxide synthase (NOS2) resulting in increased NO production. NO contributes to cell signaling by inducing posttranslational protein modifications. Under pathological conditions there is a shift from the signal transducing actions to the formation of protein tyrosine nitration by secondary products like peroxynitrite and nitrogen dioxide. We identified amyloid β (Aβ) as an NO target, which is nitrated at tyrosine 10 (3NTyr(10)-Aβ). Nitration of Aβ accelerated its aggregation and was detected in the core of Aβ plaques of APP/PS1 mice and AD brains. NOS2 deficiency or oral treatment with the NOS2 inhibitor L-NIL strongly decreased 3NTyr(10)-Aβ, overall Aβ deposition and cognitive dysfunction in APP/PS1 mice. Further, injection of 3NTyr(10)-Aβ into the brain of young APP/PS1 mice induced β-amyloidosis. This suggests a disease modifying role for NOS2 in AD and therefore represents a potential therapeutic target.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21903077     DOI: 10.1016/j.neuron.2011.07.001

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  123 in total

1.  A model of nitric oxide induced α-synuclein misfolding in Parkinson's disease.

Authors:  David K Stone; Tomomi Kiyota; R Lee Mosley; Howard E Gendelman
Journal:  Neurosci Lett       Date:  2012-07-07       Impact factor: 3.046

2.  Beyond amyloid: getting real about nonamyloid targets in Alzheimer's disease.

Authors:  Karl Herrup; Maria C Carrillo; Dale Schenk; Angela Cacace; Susan Desanti; Robert Fremeau; Ratan Bhat; Marcie Glicksman; Patrick May; Russell Swerdlow; Linda J Van Eldik; Lisa J Bain; Samantha Budd
Journal:  Alzheimers Dement       Date:  2013-07       Impact factor: 21.566

3.  S-nitrosoglutathione reduces tau hyper-phosphorylation and provides neuroprotection in rat model of chronic cerebral hypoperfusion.

Authors:  Je-Seong Won; Balasubramaniam Annamalai; Seungho Choi; Inderjit Singh; Avtar K Singh
Journal:  Brain Res       Date:  2015-08-10       Impact factor: 3.252

Review 4.  Innate immune activation in Alzheimer's disease.

Authors:  Ming-Ming Wang; Dan Miao; Xi-Peng Cao; Lin Tan; Lan Tan
Journal:  Ann Transl Med       Date:  2018-05

5.  N-Terminal Modified Aβ Variants Enable Modulations to the Structures and Cytotoxicity Levels of Wild-Type Aβ Fibrils through Cross-Seeding.

Authors:  Zhi-Wen Hu; Dan Fai Au; Letticia Cruceta; Liliya Vugmeyster; Wei Qiang
Journal:  ACS Chem Neurosci       Date:  2020-07-06       Impact factor: 4.418

6.  Role of S-nitrosoglutathione mediated mechanisms in tau hyper-phosphorylation.

Authors:  Balasubramaniam Annamalai; Je-Seong Won; Seungho Choi; Inderjit Singh; Avtar K Singh
Journal:  Biochem Biophys Res Commun       Date:  2015-01-29       Impact factor: 3.575

7.  Solid-state NMR reveals a comprehensive view of the dynamics of the flexible, disordered N-terminal domain of amyloid-β fibrils.

Authors:  Dan Fai Au; Dmitry Ostrovsky; Riqiang Fu; Liliya Vugmeyster
Journal:  J Biol Chem       Date:  2019-02-08       Impact factor: 5.157

8.  Effect of AmyTrap, an amyloid-β binding drug, on Aβ induced mitochondrial dysfunction and tau phosphorylation in cultured neuroblastoma cells.

Authors:  Omkar Gandbhir; Pazhani Sundaram
Journal:  Metab Brain Dis       Date:  2020-05-04       Impact factor: 3.584

9.  Enduring Changes in Neuronal Function upon Systemic Inflammation Are NLRP3 Inflammasome Dependent.

Authors:  Marianna M S Beyer; Niklas Lonnemann; Anita Remus; Eicke Latz; Michael T Heneka; Martin Korte
Journal:  J Neurosci       Date:  2020-06-04       Impact factor: 6.167

10.  Mrp14 deficiency ameliorates amyloid β burden by increasing microglial phagocytosis and modulation of amyloid precursor protein processing.

Authors:  Markus P Kummer; Thomas Vogl; Daisy Axt; Angelika Griep; Ana Vieira-Saecker; Frank Jessen; Ellen Gelpi; Johannes Roth; Michael T Heneka
Journal:  J Neurosci       Date:  2012-12-05       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.